<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2644">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04563208</url>
  </required_header>
  <id_info>
    <org_study_id>DUACT-101</org_study_id>
    <nct_id>NCT04563208</nct_id>
  </id_info>
  <brief_title>Study of Oral Administration of Ribavirin and Nitazoxamide Versus Placebo in COVID-19</brief_title>
  <acronym>DuACT</acronym>
  <official_title>A Randomized, Double-Blind, Study Comparing the Efficacy, Safety, and Tolerability of Oral Administration of Ribavirin (RBV) and Nitazoxamide (NTZ)Versus Placebo in SARS-CoV-2 Virus Infected Participants (DuACT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Witwatersrand, South Africa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Synavir Corporation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Witwatersrand, South Africa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, randomized, double-blind, 2-arm, parallel-group study of DuACT in&#xD;
      participants with clinical symptoms of COVID-19 that have begun within the past 48 hours&#xD;
      prior to testing.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center, randomized, double-blind, 2-arm, parallel-group study of DuACT in&#xD;
      participants with clinical symptoms of COVID-19 that have begun within the past 48 hours&#xD;
      prior to testing. A confirmatory diagnosis of COVID-19 via nasopharyngeal swab, with a&#xD;
      positive PCR result within 48 hours of testing.&#xD;
&#xD;
      Consented participants who complete screening and meet study eligibility criteria will be&#xD;
      randomized in a 1:1 ratio to receive DuACT or Placebo for 5 days.&#xD;
&#xD;
      Study drugs will be administered BID for 5 days with a loading dose on Day 1. Following&#xD;
      randomization, participants will complete a symptom questionnaire, record temperature and&#xD;
      record oxygen saturation daily for 10 days and at day 28. A thermometer and pulse oximeter&#xD;
      will be provided to each patient at the baseline visit (Day 1).&#xD;
&#xD;
      On study days 3, 6 and 10 participants will have a clinic or home visit by a home healthcare&#xD;
      provider. At these visits, a mid-turbinate nasal swab will be obtained, confirmation of the&#xD;
      patient's clinical symptoms questionnaire will be completed and any adverse events will be&#xD;
      assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 9, 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of decline in viral load</measure>
    <time_frame>10 days</time_frame>
    <description>Rate of decline in viral load over the 10 days after randomization between participants treated with RBV and NTZ for COVID-19 and placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to resolution of viral load</measure>
    <time_frame>28 days</time_frame>
    <description>Time to resolution of viral load, defined by reduction of virus below LLOQ and maintaining it for 2 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of proportion of subjects who are asymptomatic and symptomatic</measure>
    <time_frame>10 days</time_frame>
    <description>Comparison of proportion of subjects who are asymptomatic and symptomatic at day 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of decline in viral load</measure>
    <time_frame>Days 3 and 6</time_frame>
    <description>To assess the rate of decline in viral load over days 3 and 6 after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in modified NEWS-2</measure>
    <time_frame>28 days</time_frame>
    <description>Assess change in modified National Early Warning System-2 items on a scale of 0 to 20. HIgher scores meaning greater clinical risk.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with treatment emergent adverse events</measure>
    <time_frame>28 days</time_frame>
    <description>Proportion of subjects with treatment emergent adverse events leading to study drug discontinuation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Covid19</condition>
  <condition>SARS-CoV Infection</condition>
  <arm_group>
    <arm_group_label>Arm A: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Ribavirin/Nitazoxanide (RBV/NTZ)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ribavirin/Nitazoxanide (RBV/NTZ) administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered on Days 1-5</description>
    <arm_group_label>Arm A: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DuACT</intervention_name>
    <description>Day1: RBV 600 mg BID and NTZ 500 mg BID Days 2-5: RBV 400 mg BID and NTZ 500 mg BID</description>
    <arm_group_label>Arm B: Ribavirin/Nitazoxanide (RBV/NTZ)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed a current EC approved informed consent form&#xD;
&#xD;
          2. Male or female participants between 18 and 75 years of age, inclusive diagnosis of&#xD;
             SARS-CoV-2 infection, with all of the following, with onset of any within the 48 hours&#xD;
             prior to testing:&#xD;
&#xD;
               1. Presence of fever at time of screening of ≥ 38.0°C (≥ 100.0°F)&#xD;
&#xD;
               2. Presence of at least one constitutional symptom associated with Covid-19 (e.g.&#xD;
                  headache, myalgia, malaise, or fatigue, rash, diarrhea, loss or alteration of&#xD;
                  taste/smell) of any severity,&#xD;
&#xD;
               3. Presence of at least one respiratory symptom (e.g. cough, chest tightness or sore&#xD;
                  throat)&#xD;
&#xD;
          3. Diagnosis of COVID-19 with a positive PCR in the past 48 hours&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Critically ill with presence of one or more of the following signs:&#xD;
&#xD;
               1. difficulty breathing or shortness of breath&#xD;
&#xD;
               2. need for admission to a hospital or an intensive care unit,&#xD;
&#xD;
               3. acute respiratory failure requiring intubation/mechanical ventilation,&#xD;
&#xD;
               4. signs of shock including hypotension&#xD;
&#xD;
               5. Oxygen saturation &lt; 92 %&#xD;
&#xD;
          2. Any clinically significant screening laboratory results that are greater than 5 times&#xD;
             the upper limit of normal.&#xD;
&#xD;
          3. Estimated GFR &lt; 50 mL/min/1.73 m2 (calculated using either Modification of Diet in&#xD;
             Renal Disease (MDRD) or Cockcroft Gualt&#xD;
&#xD;
          4. Known genetic hemoglobinopathy (e.g., thalassemia major or sickle cell anemia) or&#xD;
             autoimmune hemolytic anemia&#xD;
&#xD;
          5. Hemoglobin less than 10 gm/dL or hematocrit &lt; 30 %&#xD;
&#xD;
          6. Retinal eye disease&#xD;
&#xD;
          7. Known chronic kidney disease, stage - 5 or receiving dialysis&#xD;
&#xD;
          8. Inability to tolerate oral medications&#xD;
&#xD;
          9. Allergy or prior adverse reaction to either ribavirin or nitazoxanide&#xD;
&#xD;
         10. QTc interval &gt; 450 mSEC for men and women&#xD;
&#xD;
         11. History of Torsade de Pointes VT or prior cardiac arrest or congenital long QT&#xD;
             interval&#xD;
&#xD;
         12. Current treatment with histamine-2 receptor antagonists (H2 blockers) and/or Protein&#xD;
             Pump Inhibitors and throughout the study.&#xD;
&#xD;
         13. Any physical, mental, or social condition, drug/alcohol use, history of illness or&#xD;
             laboratory abnormality that in the investigator's judgment might interfere with study&#xD;
             procedures or the ability of the subject to adhere to and complete the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sunnyside Office Park</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bronwyn Bosch, MBBCh</last_name>
      <phone>+27113585300</phone>
      <email>bbosch@ezintsha.org</email>
    </contact>
    <contact_backup>
      <last_name>Godspower Akpomiemie, MPH</last_name>
      <phone>+2711358 5370</phone>
      <email>gakpomiemie@ezintsha.org</email>
    </contact_backup>
    <investigator>
      <last_name>Simiso Sokhela, MBBCh</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nomathemba Chandiwana, MBBCh</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joana Woods, MBBCh</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 21, 2020</study_first_submitted>
  <study_first_submitted_qc>September 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2020</study_first_posted>
  <last_update_submitted>December 11, 2020</last_update_submitted>
  <last_update_submitted_qc>December 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Witwatersrand, South Africa</investigator_affiliation>
    <investigator_full_name>Willem Daniel Francois Venter</investigator_full_name>
    <investigator_title>Divisional Director: Ezintsha</investigator_title>
  </responsible_party>
  <keyword>Ribavirin</keyword>
  <keyword>Nitazoxanide</keyword>
  <keyword>SARS-CoV-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

